This clinical trial is focused on studying a condition known as Hereditary Angioedema (HAE). HAE is a rare genetic disorder that causes sudden swelling in various parts of the body, such as the face, hands, and feet. The treatment being studied in this trial is a medication called Berotralstat, which is taken orally in the form of a capsule. Berotralstat is designed to help prevent the swelling attacks associated with HAE.

The purpose of this study is to monitor the long-term safety of Berotralstat in individuals who have previously participated in Berotralstat studies. Participants in this trial will continue to take Berotralstat over an extended period, allowing researchers to gather important information about its safety and any potential side effects. The study will provide ongoing access to Berotralstat for those who have been part of earlier clinical trials, ensuring they can continue their treatment while contributing to valuable research.

Throughout the study, participants will be monitored for any treatment-related side effects or serious adverse events. The trial will continue until another way to access the medication becomes available, or until the sponsor decides to stop the global development and commercialization of Berotralstat. This study aims to ensure that Berotralstat remains a safe and effective option for managing Hereditary Angioedema in the long term.